Cargando…
Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report
RATIONALE: Dabigatran is a direct thrombin inhibitor that is widely used to prevent the formation of thrombus formation. Amiodarone can increase the plasma concentration of dabigatran. CES1 (carboxylesterase 1) and ABCB1 (ATP-binding cassette subfamily B member 1) genetic polymorphisms associate wit...
Autores principales: | Wu, Tingting, Xia, Xiaotong, Fu, Jinglan, Chen, Wenjun, Zhang, Jinhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478673/ https://www.ncbi.nlm.nih.gov/pubmed/32899083 http://dx.doi.org/10.1097/MD.0000000000022084 |
Ejemplares similares
-
Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect
por: Gu, Zhi-Chun, et al.
Publicado: (2018) -
The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation
por: Zhu, Zhu, et al.
Publicado: (2022) -
Anticoagulation efficacy of dabigatran etexilate for left atrial appendage thrombus in patients with atrial fibrillation by transthoracic and transesophageal echocardiography
por: Xing, Xiao Fei, et al.
Publicado: (2018) -
A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation
por: Wei, Zhonghai, et al.
Publicado: (2016) -
Does the CHA(2)DS(2)-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?
por: Michalska, Anna, et al.
Publicado: (2020)